Merck Animal Health Expands Vaccine Portfolio and Manufacturing Capabilities with Acquisition of Prondil S.A.
The company’s wide range of products are sold in over 20 countries.
MADISON, N.J., December 6– Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has acquired Prondil S.A., a privately-held company specializing in development and manufacturing of animal health vaccines for livestock. Specific terms of the agreement were not disclosed.
Prondil, located in Montevideo, Uruguay, is an internationally-recognized supplier of quality antigens and vaccines for veterinary use. The company’s wide range of products are sold in over 20 countries.
“At Merck Animal Health we continue to execute upon our strategy to expand our vaccine leadership and add more breadth to our portfolio,” said Rick DeLuca, President, Merck Animal Health. “This acquisition of Prondil provides expertise and biologics manufacturing capacity as well as a complementary portfolio of specialized livestock vaccines.”
Vaccines play an important role in protecting animal and public health. Timely and effective vaccination reduces the incidence and severity of disease, enabling efficient production of food animals.
About Merck Animal Health
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook and Twitter at @MerckAH.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).